Lewis, Sandy http://orcid.org/0000-0003-0463-7482
Romano, Carla
De Bruecker, Geert
Murrough, James W.
Shelton, Richard
Singh, Jaskaran B.
Jamieson, Carol
Clinical trials referenced in this document:
Documents that mention this clinical trial
Analysis of Clinical Trial Exit Interview Data in Patients with Treatment-Resistant Depression
https://doi.org/10.1007/s40271-019-00369-8
Documents that mention this clinical trial
Analysis of Clinical Trial Exit Interview Data in Patients with Treatment-Resistant Depression
https://doi.org/10.1007/s40271-019-00369-8
Funding for this research was provided by:
Janssen Pharmaceuticals
Article History
First Online: 4 July 2019
Compliance with Ethical Standards
:
: The study was conducted by RTI Health Solutions, which received consultancy fees from Janssen Pharmaceuticals. RTI Health Solutions and Janssen Pharmaceuticals were involved in the analysis and interpretation of data and the decision to submit these data for publication. Funding for the preparation of this article was provided by Janssen Pharmaceuticals. RTI Health Solutions is a research unit of RTI International, a not-for-profit research institute.
: Sandy Lewis and Carla (DeMuro) Romano are employees of RTI Health Solutions. Geert De Bruecker is an independent healthcare practitioner specializing in the field of psychiatry and has no conflicts of interest that are directly relevant to the content of this article. Jaskaran B. Singh and Carol Jamieson are employees of Janssen Pharmaceuticals. James W. Murrough is an employee of the Icahn School of Medicine at Mount Sinai. In the past 3 years, he has provided consultation services to Allergan, Fortress Biotech, Novartis, Janssen Research and Development, Genentech, ProPhase, and Global Medical Education and has received research support from Avanir Pharmaceuticals. He is named on a patent pending for neuropeptide Y as a treatment for mood and anxiety disorders. The Icahn School of Medicine at Mount Sinai (to which James W. Murrough is affiliated) is named on a patent and has entered into a licensing agreement and will receive payments related to the use of ketamine if it is approved for the treatment of depression. James W. Murrough is not named on the patent and will not receive any payments. Richard Shelton is an employee of the University of Alabama at Birmingham School of Medicine. In the past 3 years, he has provided consultation to Acadia Pharmaceuticals, Allergan Inc., Cerecor, Inc., Clintara, LLC, Janssen Pharmaceutica, Lundbeck A/S, Medtronic, Inc., MSI Methylation Sciences, Inc., Naurex, Inc., Nestle’ Health, Pfizer, Inc., and Takeda Pharmaceuticals. He has received grant support from Acadia Pharmaceuticals, Alkermes, Inc., Allergan Inc., Assurex Health, Avanir Pharmaceuticals, Cerecor, Inc., Genomind, Intracellular Therapies, Janssen Pharmaceutica, Nestle’ Health, Otsuka Pharmaceuticals, and Takeda Pharmaceuticals.
: This project was reviewed and approved by an institutional review board, and all procedures were in accordance with the ethical standards of the 1964 Helsinki Declaration and its later amendments.
: Written informed consent was obtained from all participants prior to study participation.